Compositions and methods for treatment of angiogenesis-associated ocular disorders
The invention provides methods and compositions for identifying and quantifying pathological changes on the retina.
1. A method of identifying retinal pathological neovascularization of a subject comprising locally administering to the retina of said subject a composition comprising a peptide consisting of the amino acid sequence of SEQ ID NO: 1, 2, or 3 that binds to pathological neovessels, and detecting binding of said peptide to retinal blood vessels of said subject, wherein said binding indicates retinal pathological neovascularization.
2. The method of claim 1 , wherein said peptide is fluorescently labeled.
3. The method of claim 1 , wherein said composition is in the form of eye drops, ointment, gel, or an ocular insert.
4. The method of claim 2 , wherein said peptide is labeled with a fluorescent molecule selected from the group consisting of rhodamine, ethidium bromide, fluorescein, green fluorescent protein (GFP), or fluorescein isothiocyanate (FITC).
5. A method of treating retinal pathological neovascularization of an ophthalmic condition or disorder selected from retinopathy of prematurity, diabetic retinopathy, and age-related macular degeneration in a subject in need thereof comprising the steps of:
(a) identifying a subject with the ophthalmic condition or disorder; and
(b) locally administering to the retina of said subject a peptide consisting of the amino acid sequence of SEQ ID NO: 1, 2, or 3, linked to an anti-angiogenic agent selected from the group consisting of, angiopoietin-2, angiostatin, endostatin, tumstatin, pigment epithelium-derived factor, and a VEGF inhibitor, and a pharmaceutically acceptable carrier, thereby reducing pathological neovascularization.
6. The method of claim 5 , wherein said peptide linked to said anti-angiogenic agent is in the form of eye drops, ointment, gel, or an ocular insert.